Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to assess the safety, tolerability, antiviral effects, and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01247194
Study type Interventional
Source Presidio Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 1
Start date October 2010
Completion date June 2011

See also
  Status Clinical Trial Phase
Withdrawn NCT00895882 - Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN) Phase 2